An enzyme-linked immunosorbent assay for hypoxia marker binding in tumours
1994

Measuring Hypoxia in Tumors with ELISA

Sample size: 12 publication Evidence: moderate

Author Information

Author(s): J.A. Raleigh, J.K. La Dine, J.M. Cline, D.E. Thrall

Primary Institution: UNC School of Medicine; North Carolina State University

Hypothesis

The binding of CCI-103F reflects the presence of hypoxia in tumors.

Conclusion

The ELISA developed for measuring CCI-103F binding provides a sensitive method for assessing tumor hypoxia without the need for radioactive reagents.

Supporting Evidence

  • The ELISA allows for the measurement of hypoxia marker binding in multiple biopsy samples.
  • Preliminary studies indicated the usefulness of the ELISA approach for assessing tumor hypoxia.
  • The study demonstrated that the ELISA can detect binding in most spontaneous canine tumors.

Takeaway

Scientists created a test to see if tumors are low on oxygen, which can make them harder to treat. This test is easier and safer because it doesn't use radioactive materials.

Methodology

The study involved developing an ELISA to measure the binding of CCI-103F in tumor biopsies, comparing it with radioactivity from tritiated CCI-103F.

Limitations

The study's findings may not directly correlate with absolute hypoxic fractions in clinical settings due to variability in binding intensities among different tumors.

Participant Demographics

Canine patients with spontaneous tumors.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication